World Health Organization Raises Concern Over Acute Lack of Weight-Loss Medications
Under 10% of people that would benefit from obesity jabs like Wegovy have access to them, caution the global health agency as it publishes its inaugural recommendations on the drugs.
With in excess of 1,000,000,000 people worldwide now classified as obese, it is urging increased and just availability to this class of drugs.
According to projections, more than two billion could be obese by 2030 without intervention.
"The latest guidelines recognises that obesity is a chronic disease that can be treated with thorough and lifelong treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and logistical bottlenecks are significant barriers to widespread availability to the treatments that can help people shift considerable weight, says the organization.
GLP-1 Therapy Shortage
Even in the current most favorable outlook, the manufacturing of such drugs might only reach around 100 million people – less than 10% of eligible patients, according to the health organization.
The recommendation encourages nations and manufacturers to expand availability, through strategies such as licensing agreements.
A patent on a key compound – the core ingredient of a leading brand – is scheduled to end in several nations in 2026.
The Way Weight-Loss Jabs Work
These medications replicate a biological compound to delay gastric emptying, suppress the appetite and boost the sense of being full so users consume fewer calories.
Individuals commonly see weight reduction within a few weeks of commencing the once-weekly jabs.
Evidence points to users may see weight return a year later of discontinuing the drug, as their typical hunger return.
To be overweight or obese raises your chance for developing diseases, such as type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.
Excess weight affects individuals in every country and was linked to over three and a half million deaths worldwide in 2024, as per the WHO.